Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Phase II Trial of Intravenous Ascorbic Acid (Vitamin C) as an Adjunct to Pazopanib in the First-Line or Post-Immunotherapy Setting for Metastatic or Unresectable Clear Cell Renal Cell Carcinoma (ccRCC)

NCT03334409 is registered in ClinicalTrials.gov with Academic and Community Cancer Research United as lead sponsor.

NCT NCT03334409
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03334409 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Phase II Trial of Intravenous Ascorbic Acid (Vitamin C) as an Adjunct to Pazopanib in the First-Line or Post-Immunotherapy Setting for Metastatic or Unresectable Clear Cell Renal Cell Carcinoma (ccRCC)
Lead sponsor
Academic and Community Cancer Research United
Phase
Phase 2
Overall status
Terminated
Start date
February 16, 2018
Completion date
March 13, 2021
Enrollment
5 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

clear cell renal cell carcinoma, metastatic clear cell renal cell carcinoma, stage iii renal cell cancer ajcc v8, stage iv renal cell cancer ajcc v7, unresectable renal cell carcinoma